Gradient Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Gradient Health provides a medical imaging data platform giving AI researchers and healthcare companies access to de-identified radiology datasets for model training and validation.
About
Gradient Health is a healthcare data company founded in 2019 that operates a platform providing access to de-identified medical imaging data for AI development, research, and regulatory validation. The company partners with health systems and imaging centers to source, de-identify, and structure radiology datasets including X-rays, CT scans, MRI studies, and pathology images that AI developers need to train and validate clinical algorithms. Obtaining sufficient high-quality labeled medical imaging data has been one of the primary bottlenecks for AI medical imaging companies, and Gradient Health addresses this by creating a market for compliant data access. The company uses advanced de-identification techniques that go beyond HIPAA minimum requirements to ensure patient privacy while preserving the clinical detail that makes datasets useful for AI training. Gradient serves medical imaging AI companies, pharmaceutical companies conducting imaging biomarker research, and academic medical centers building AI models. The company has built relationships with health systems across the US and has assembled imaging datasets spanning millions of studies across diverse patient populations and imaging equipment types.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.